is continues to and healthy remain Raj, you, everyone everyone. good and hope Thank I morning, safe.
new company. the revenue record from was Our quarter our sequentially and million quarter increased a quarter. for the up fourth quarter third fourth XX% XXXX of of represents $XX revenue Fourth from XX%
the and our are the saw over are that we the are course latest moving much growth results very story XXXX we of and intact. of strong recovery Our foundations evidence that pandemic beyond the
implants on focus in to resonate our marketplace. continues safety Our superior of and and women’s the the profile aesthetic singular health
measures now over October our X% last year of least than less than X.X report safety We rupture. implant to to and with in an key grow we worldwide, results competitor anything at magnitude data seen Motiva legacy post-market shared contracture of surveillance These capsular markets. In international implants year, total of share. ten the better continue market order the we complication rate Implants our a of from continue the global the products in million are
this beyond As women impressive it how It competitive perceive change breast this as new as to the augmentation that put of believe safety aesthetic is, data and Establishment change data just At speaks as grow something should lightly procedures. we available, the substantially. are just believe total market addressable is perceptions we Labs, our that possibilities and game-changing literally outcomes not become and possible quite could advantage.
been breast on being Another offer is world, area eight that less women alternative In countries have to where to aesthetic around segment many One reconstruction focus with is has the important an this achieving the by in mastectomy. in the breast of able an after reconstruction historical of XX% working afflicted not change better for reason a than have found perceptions women we breast are cancer the world for less than is substantially a mission women reconstruction one breast company. a of outcome. XX%
with new most an an outcome matches just XXXX have breast but aesthetic breast patients’ was for – our surgery. step to reconstructions launch aesthetic Establishment not we was not also cash reconstruction while The with the important pandemic, to Establishment tissue spending our to aesthetic at Labs, difficult during we and a is goal and for to and because this conserved strategically important of the better it for initiatives. solution is showed our times. to these did year solution allow Flora reduced also in that these planned the breast We invest tested it company an Our tested the safer customer-facing We manage with year because create Labs, comfort an patients. but height of better protected patients. headcount our XXXX offering important more important well of a where team. much in traditional can reduced people, continuing standard important augmentation expander commercial
fourth Our and and team capital our quarter. operating shape our balance in great and sheet cash working managed $XX.X in remains balance million well with expenses Renee in cash. finance increased her the
part our in Japan, with commanding company we invest front over in XXXX intend As in are year, social the fabric that worst Canada, on last message significant educational online surgeons us of we Europe, digital customers manufacturing, with us, given opportunities our media, the our is impressive and presence On jurisdictions. has our the training best-in-class no and digital been our we Brazil, as women’s this of also other the passed future. we the Motiva covers MDSAP of focus that to health the well outcomes. major of of observations. potential under and and attracted Australia, discipline improved increasingly as USFDA, Program pandemic audit Audit making of is XXXX annual our In validated MDSAP many have has still to safety trained and for resources. with confident new we aesthetic behind in just regulators Single week, programs, thousands requirements the our plastic as and last Edge standard built a
helps answers level of interest. media of us This support us she allows We to as have times competitor. XX to than engagement closest a provide areas research patient’s customized specific journey social our to of our engagement more conducts and
into activity our team procedures. on also aesthetic leverage decision-making as seek presence they digital-based focused our breast unmatched to insights mind women’s initiatives level marketing to provide This of is in valuable industry. Our is
strong last continued growth the have us and foreseeable challenging our for our even resiliency that us, the we year results all has As in strong business financial been confident for future. of the as will makes more
we the detail XX% full for in Renee results of provide guidance moment. which fourth XXXX are will year our from momentum, a outlook and of financial providing on growth Given XXXX. of This million. $XXX million the more over to has carried the our $XXX XX% quarter, over represents to
had I call to near-term invasive surgeons with Before to X, an her, On on scars and on XXX meeting goal and for our less minimally I be without industry no matches we developed tuned industry along have with investor showcasing outstanding. have hosted simple been Mia, has Motiva decades been we and and February A in provide feedback we in is over safe. done than this breast several virtual significant general a has procedure, work we turn initiatives. perform, minutes done and plastic that strong the Mia, a minimally in participation want that update our we enhancement the breast procedure one over and enhancement the with to that visible XX reproducible development that goal can invasive feel system anesthesia
world, December advancing billion received We discharged as just market women Based very expansion ErgonomixX performing breast Mia the procedures. regulatory as who have over breast opens Mia learned with size XX to market discomfort. a as expansive to four reduce for the and to the aesthetics. we The the considered and Implant series system. in minutes. procedures able patients two fast addressable all initial tremendous only XX than more to for very from to cases. our Mia. tools with breast had many the curve amount The this overall times for with Motiva by to less Mia on than early of market in initial is little traditional are of around three their surgery of $X.X billion Mark Motiva opportunity pain as in million total research surgeons with back learning for after XX% CE low we are fell increase to the procedure global now up with that process enhancement part is $X as work conducted Recovery Mia Motiva women X.X will our time Mia previously implants This our estimate minutes also year. technology with proprietary Diamond days the fast is market used series our not a with and in breast market X,XXX little or view procedure The in
We strategy near define and commercial our in detail continue we future. to the will share more
CE features new and offering of ergonomics was implant also upon properties, ErgonomixX in even Round which greater platform in and implant enhanced Pacific. mechanical we and product satisfaction. become improved Marked December. chemistry, builds believe Asia most our ErgonomixX result will best our patient innovative has Our The in Europe this The advanced successful Ergonomix including, selling premium
a command Ergonomix. feature-rich, expect over As it to so we is price premium ErgonomixX
very been has Our in early ErgonomixX implants Latin with America experience positive.
SmoothSilk the track With a are several underway we expander We already and novel centers commercial which compatible are port, Europe Europe over ErgonomixX and Motiva reconstruction over activity RFID forward summer. implants with contract early are for our have Europe the summer surface. Renowned in significant for in in on our XXXX. will commercial Mark is Flora discussions activities the tissue standard-of-care. bio-engineered the improvement including unique received Flora market with accounts. years it the Pre-marketing them in expander a MRI current on expander tissue proprietary looking integrated to tissue used caring be CE launch offers begin an hospital Flora, breast the June with in are features for to broad only of the over preparation and in
this progress we commercial important in and toward and launching continues China clinical XXXX. are in market in Our moving
than reached IDE the to anniversaries. patients now also will remain Our two aesthetic regulatory I year post-op unchanged. in the half approval More now U.S. have cohorts timelines over U.S. call of Renee. for turn our their study
